Key result
Current smoking is not independently linked to lower in-hospital mortality after adjusting for baseline differences.
Why the study?
Does current smoking improve outcomes in patients receiving thrombolytic therapy for myocardial infarction?
Cohort (n=1,619)
Single-blind
Yes
Does current smoking improve outcomes in patients receiving thrombolytic therapy for myocardial infarction?
Absolute Event Rate: 4% vs 8.9%
p-value: p=0.0001
The apparent survival benefit of smoking in patients receiving thrombolysis for myocardial infarction is driven by favorable baseline characteristics (younger age, less severe disease) rather than an independent protective effect.
No takes yet. Share an insight, caveat, or question.
Apparent mortality benefit of smoking in thrombolyzed MI is confounded by baselines; leaves open any independent effect after adjustment.
Grines et al. (1995) conducted a cohort in Myocardial Infarction (n=1,619). Current smoking vs. Nonsmoking was evaluated on In-hospital mortality (p=0.0001). Current smoking was associated with lower in-hospital mortality than nonsmoking (4.0% vs 8.9%, P=0.0001), but this lost independent prognostic significance after adjusting for baseline differences.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: